2,3 Detailed results presented from SYNCHRONIZE-MASLD, showed that the trial met both its primary endpoints, with additional results showing that, relative to baseline, liver fat normalization was reached by 6 out of 10 participants living with metabolic dysfunction-associated steatotic liver disease (MASLD) and obesity or overweight who were treated with survodutide after 48 weeks
Okojie's virtual Semaglutide consultations a convenient and effective solution for your weight loss journey
10.1002/emmm.201302451 336
Review gastric sleeve, gastric bypass, nutrition labs, hydration risk, medication safety, and when bariatric follow-up is still needed
Whats Coming Next for GLP-1 and Metabolic Disease Treatment Moving from academia to industry led to advancing groundbreaking diabetes and obesity therapies